International Bladder Cancer Update Archives

High-Risk/BCG Naïve: Treatment of Choice

Michael A. O’Donnell, MD, discusses BCG’s role as the standard treatment for non-muscle invasive bladder cancer (NMIBC).

Yair Lotan, MD, discusses urinary biomarkers and highlights their evolving role in bladder cancer detection and surveillance.

Siamak Daneshmand, MD, covers recent updates in bladder cancer guidelines, focusing on the 2024 NCCN and AUA recommendations.

Amirali Salmasi, MD, MSCR, explores the rationale for systemic immunotherapy in non-muscle invasive bladder cancer.

Alexandra Drakaki, MD, PhD, explores circulating tumor DNA in bladder cancer, highlighting its potential as a biomarker.

Gopalkumar Iyer, MD, explores the role of genomic alterations in predicting response to neoadjuvant chemotherapy for muscle-invasive bladder cancer.

Bernard H. Bochner, MD, FACS, examines the extent of lymph node dissection in bladder cancer surgery and its impact on oncologic outcomes.

Arlene O. Siefker-Radtke, MD, explores the evolving role of erdafitinib in treating FGFR3-altered urothelial carcinoma.

Shilpa Gupta, MD, explores the evolving treatment paradigm in metastatic urothelial carcinoma following the EV-302 trial.

Jennifer A. Linehan, MD, examines strategies for managing upper tract UTUC, highlighting diagnosis, staging, and treatment selection.

Piyush K. Agarwal, MD, explores the evolving landscape of treatments for BCG-unresponsive bladder cancer.

Robert Dreicer, MD, MS, MACP, FASCO, highlights the complexities of managing high-grade urothelial carcinoma of the upper tract.